Welcome to our dedicated page for Immuron news (Ticker: IMRN), a resource for investors and traders seeking the latest updates and insights on Immuron stock.
Immuron Limited develops and commercializes orally delivered targeted polyclonal antibodies for gastrointestinal infectious diseases. The Australian biopharmaceutical company uses a hyper-immune bovine colostrum platform and markets Travelan®, an over-the-counter product for travelers’ diarrhea and digestive tract protection, in Australia, the United States and Canada.
Recurring news covers Travelan sales by region, the Australian launch of ProIBS®, research funding and collaborations for enteric pathogens, and updates on clinical programs such as IMM-124E and IMM-529. Company announcements also discuss operating results, strategic updates, distribution expansion and investor conference presentations tied to its ASX and Nasdaq listings.
Immuron (ASX: IMC; NASDAQ: IMRN) has announced an upcoming investor webinar on MarketOpen Direct Connect. The event is scheduled for Thursday, August 8, 2024, at 11:00 AM AEST (9:00 AM AWST). CEO Steven Lydeamore will provide an update on additional data analysis of the IMM-124E (Travelan®) Phase 2 trial and discuss next steps.
The webinar will include a moderated Q&A session allowing attendees to ask questions directly to Mr. Lydeamore. Interested parties can register for free via the provided Zoom link. A recorded version of the webinar will be made available after the event.
Immuron (ASX: IMC; NASDAQ: IMRN) has reported record global sales for its over-the-counter immune supplement Travelan® in FY 2024. Global sales reached AUD$4.9 million, up 174% from the previous year. Australia led with AUD$3.7 million in sales, a 223% increase, while the USA achieved record sales of AUD$1.1 million, up 74%. The June 2024 quarter saw significant growth, with global sales up 253% year-over-year to AUD$1.3 million.
The company attributes this success to increased brand awareness investments and plans further growth in North America through increased brand investment and distribution. The sales surge aligns with rising international travel, as reported by the Australian Bureau of Statistics and the U.S. International Trade Administration.
Immuron (ASX: IMC; NASDAQ: IMRN) has filed a pre-IND application with the FDA for IMM-529, aimed at treating recurrent Clostridioides difficile infections (CDI). CDI affects over 400,000 people annually in the U.S., causing over 30,000 deaths. IMM-529 is being developed as an adjunct therapy to standard antibiotics, targeting Toxin B, spores, and vegetative cells of C. diff. Pre-clinical studies have shown promising results, including 80% prevention of primary disease and 67% protection against recurrence. The projected base case yearly revenue for IMM-529 is US$93 million, with potential expansion to US$141 million if used for first recurrence patients. The drug's oral dosing is considered advantageous over current complex treatments. Immuron is working with Monash University to produce antibodies from bovine colostrum. The PR highlights the urgent need for new CDI treatments due to rising antibiotic resistance.
Immuron's CEO, Steven Lydeamore, will present at the Emerging Growth Conference on June 13, 2024. Immuron, an Australian biopharmaceutical company traded on ASX (IMC) and NASDAQ (IMRN), invites individual and institutional investors, as well as advisors and analysts, to join the interactive presentation. The session starts at 2:00 PM US Eastern Standard Time and will last for 12 minutes. Participants are encouraged to submit questions in advance or during the event. If unable to attend live, an archived webcast will be available on EmergingGrowth.com and its YouTube channel.
Immuron CEO Steven Lydeamore will be presenting at Peak Asset Management's Peak Sky High luncheon in Melbourne on June 1, 2024.
Immuron , an Australian-based biopharmaceutical company, is listed on the ASX as IMC and NASDAQ as IMRN.
The presentation slide deck is available on the company's website.
This press release was authorized by the directors of Immuron.
Immuron (IMRN), an Australian biopharmaceutical company, announced significant board changes on May 31, 2024. Dr. Roger Aston resigned as Non-Executive Director after serving since 2012, including as Chairman until 2023. Over his tenure, Immuron advanced its commercial and clinical programs, especially in diarrhoea prevention and gut health, strengthened by its partnership with the US Military. Dr. Aston's leadership was pivotal during capital raisings and the COVID-19 pandemic. Effective June 1, 2024, Dr. Jeannie Joughin, with extensive experience in immunology and senior roles at major pharmaceutical companies, will join as a Non-Executive Director, expected to enhance Immuron's strategic and commercial direction.
Immuron , an Australian biopharmaceutical company, will be presenting at the Emerging Growth Conference on May 8, 2024. Investors, analysts, and advisors can interact with the CEO, Steven Lydeamore, during the live event. Questions can be submitted in advance or during the presentation.
Immuron announces the resignation of Non-Executive Director Stephen Anastasiou to focus on other business interests. Stephen has been with the company since 2013, contributing to the launch of Travelan® in the USA and Canadian markets and dual listing on NASDAQ (IMRN). His departure is aimed at restructuring his business commitments to spend more time with family and pursue personal interests. Immuron Chairman expresses gratitude for Stephen's marketing and clinical contributions and wishes him success in future endeavors.
Summary not available.
Summary not available.